Director, Patient Focused Drug Development and Innovation
Sarepta· Cambridge, MA
hybrid director $186k – $232k / year seen live 23h ago
Why Sarepta? Why Now? The promise of genetic medicine has arrived, and Sarepta is at the forefront. We hold a leadership position in Duchenne muscular dystrophy (Duchenne) and are building a robust portfolio of programs across muscle, central nervous system, and cardiac
This link goes straight to the employer's workday page. We last confirmed it was open 23h ago.